Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Hepatoblastoma 1

Interventions

Methotrexate 29Cytarabine 28Vincristine 26Cyclophosphamide 25Mercaptopurine 20Dexamethasone 20pegaspargase 18Prednisone 17Doxorubicin 17Daunorubicin 16Asparaginase 15merphos 14Calcium Dobesilate 14Thioguanine 13Leucovorin 13Radiotherapy 11Hydrocortisone 10azathiopurine 9Filgrastim 9Etoposide 9Granulocyte Colony-Stimulating Factor 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Specimen Handling 7prednylidene 6deltacortene 6Whole-Body Irradiation 6Methylprednisolone 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Precursor Cell Lymphoblastic Leukemia-Lymphoma × MLN 8237 × Clear all
NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Children's Oncology Group

Phase 2 Completed
118 enrolled 24 charts
CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡